| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $504,601 ) |
| | 2025 | 2025 | ORTHOLEVO, INC. | 6 HART RD | LYNNFIELD | MA | 01940-2415 | ESSEX | USA | SB1AR084380 | Late Stage Development of Sustained-release Relaxin for Treating Joint Contracture | 002 | 2 | NIH | 7/21/2025 | $504,601 |
| | 2025 | 2024 | ORTHOLEVO, INC. | 6 HART RD | LYNNFIELD | MA | 01940-2415 | ESSEX | USA | SB1AR084380 | Late Stage Development of Sustained-release Relaxin for Treating Joint Contracture | 001 | 1 | NIH | 6/2/2025 | $0 |
| | 2025 | 2024 | ORTHOLEVO, INC. | 6 HART RD | LYNNFIELD | MA | 01940-2415 | ESSEX | USA | SB1AR084380 | Late Stage Development of Sustained-release Relaxin for Treating Joint Contracture | 000 | 1 | NIH | 10/9/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $504,965 ) |
| | 2024 | 2024 | ORTHOLEVO, INC. | 6 HART RD | LYNNFIELD | MA | 01940-2415 | ESSEX | USA | SB1AR084380 | Late Stage Development of Sustained-release Relaxin for Treating Joint Contracture | 000 | 1 | NIH | 8/6/2024 | $504,965 |
| | 2024 | 2022 | ORTHOLEVO, INC. | 36 MUZZEY ST | LEXINGTON | MA | 02421-5214 | MIDDLESEX | USA | R44AR079326 | Enabling Studies for the Treatment of Frozen Shoulder Using Relaxin | 001 | 2 | NIH | 5/31/2024 | $0 |
| | 2024 | 2022 | ORTHOLEVO, INC. | 36 MUZZEY ST | LEXINGTON | MA | 02421-5214 | MIDDLESEX | USA | R44AR079326 | Enabling Studies for the Treatment of Frozen Shoulder Using Relaxin | 000 | 2 | NIH | 5/29/2024 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $914,843 ) |
| | 2022 | 2022 | ORTHOLEVO INC | 36 MUZZEY ST | LEXINGTON | MA | 02421-5214 | MIDDLESEX | USA | R44AR079326 | Enabling Studies for the Treatment of Frozen Shoulder Using Relaxin | 000 | 2 | NIH | 7/26/2022 | $914,843 |
|
| Issue Date FY: 2021 ( Subtotal = $786,298 ) |
| | 2021 | 2021 | ORTHOLEVO, INC. | 36 MUZZY ST | LEXINGTON | MA | 02421-5214 | MIDDLESEX | USA | R44AR079326 | Enabling Studies for the Treatment of Frozen Shoulder Using Relaxin | 000 | 1 | NIH | 7/9/2021 | $786,298 |
|
|
